These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 30335831)

  • 21. Estimation and visualization of heterogeneous treatment effects for multiple outcomes.
    Yuki S; Tanioka K; Yadohisa H
    Stat Med; 2023 Feb; 42(5):693-715. PubMed ID: 36574770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of biomarker-by-treatment interactions in randomized clinical trials with survival outcomes and high-dimensional spaces.
    Ternès N; Rotolo F; Heinze G; Michiels S
    Biom J; 2017 Jul; 59(4):685-701. PubMed ID: 27862181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A nonparametric method for value function guided subgroup identification via gradient tree boosting for censored survival data.
    Zhang P; Ma J; Chen X; Shentu Y
    Stat Med; 2020 Dec; 39(28):4133-4146. PubMed ID: 32786155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Model averaging for treatment effect estimation in subgroups.
    Bornkamp B; Ohlssen D; Magnusson BP; Schmidli H
    Pharm Stat; 2017 Mar; 16(2):133-142. PubMed ID: 27935199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cell-free and circulating tumor cell-based biomarkers in men with metastatic prostate cancer: Tools for real-time precision medicine?
    Miyamoto DT; Lee RJ
    Urol Oncol; 2016 Nov; 34(11):490-501. PubMed ID: 27771279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long range personalized cancer treatment strategies incorporating evolutionary dynamics.
    Yeang CH; Beckman RA
    Biol Direct; 2016 Oct; 11(1):56. PubMed ID: 27770811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment evaluation for a data-driven subgroup in adaptive enrichment designs of clinical trials.
    Zhang Z; Chen R; Soon G; Zhang H
    Stat Med; 2018 Jan; 37(1):1-11. PubMed ID: 28948633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psychosocial interventions for men with prostate cancer.
    Parahoo K; McDonough S; McCaughan E; Noyes J; Semple C; Halstead EJ; Neuberger MM; Dahm P
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008529. PubMed ID: 24368598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review.
    Ondra T; Dmitrienko A; Friede T; Graf A; Miller F; Stallard N; Posch M
    J Biopharm Stat; 2016; 26(1):99-119. PubMed ID: 26378339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of subpopulations with distinct treatment benefit rate using the Bayesian tree.
    Shen C; Hu Y; Li X; Wang Y; Chen PS; Buxton AE
    Biom J; 2016 Nov; 58(6):1357-1375. PubMed ID: 27356196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms.
    Gulati R; Cheng HH; Lange PH; Nelson PS; Etzioni R
    Cancer Epidemiol Biomarkers Prev; 2017 Feb; 26(2):222-227. PubMed ID: 27742670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detecting treatment-covariate interactions using permutation methods.
    Wang R; Schoenfeld DA; Hoeppner B; Evins AE
    Stat Med; 2015 May; 34(12):2035-47. PubMed ID: 25736915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Confidence Interval Estimation for Sensitivity to the Early Diseased Stage Based on Empirical Likelihood.
    Dong T; Tian L
    J Biopharm Stat; 2015; 25(6):1215-33. PubMed ID: 25372999
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Test Statistics and Confidence Intervals to Establish Noninferiority between Treatments with Ordinal Categorical Data.
    Zhang F; Miyaoka E; Huang F; Tanaka Y
    J Biopharm Stat; 2015; 25(5):921-38. PubMed ID: 24919157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simple subgroup approximations to optimal treatment regimes from randomized clinical trial data.
    Foster JC; Taylor JM; Kaciroti N; Nan B
    Biostatistics; 2015 Apr; 16(2):368-82. PubMed ID: 25398774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A general statistical framework for subgroup identification and comparative treatment scoring.
    Chen S; Tian L; Cai T; Yu M
    Biometrics; 2017 Dec; 73(4):1199-1209. PubMed ID: 28211943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparative study of subgroup identification methods for differential treatment effect: Performance metrics and recommendations.
    Alemayehu D; Chen Y; Markatou M
    Stat Methods Med Res; 2018 Dec; 27(12):3658-3678. PubMed ID: 28629264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ensemble survival trees for identifying subpopulations in personalized medicine.
    Chen YC; Chen JJ
    Biom J; 2016 Sep; 58(5):1151-63. PubMed ID: 27073016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis.
    Lueza B; Rotolo F; Bonastre J; Pignon JP; Michiels S
    BMC Med Res Methodol; 2016 Mar; 16():37. PubMed ID: 27025706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. On optimal treatment regimes selection for mean survival time.
    Geng Y; Zhang HH; Lu W
    Stat Med; 2015 Mar; 34(7):1169-84. PubMed ID: 25515005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.